<DOC>
	<DOCNO>NCT00853294</DOCNO>
	<brief_summary>The objective open-label , randomize , two-period , crossover study evaluate oral bioavailability Mallinckrodt extend release test capsule formulation chlorpheniramine polistirex/hydrocodone polistirex compare equivalent oral dose commercially available extended release oral suspension chlorpheniramine polistirex/hydrocodone polistirex ( Tussionex速 Pennkinetic速 Extended Release Oral Suspension , Celltech Pharmaceuticals , Inc. ) test group healthy subject fast condition .</brief_summary>
	<brief_title>Fasting Study Chlorpheniramine Polistirex Hydrocodone Polistirex Capsules Tussionex速 Pennkinetic速 Extended Release Oral Suspension</brief_title>
	<detailed_description />
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female , 18 year age old . 2 . Female subject must postmenopausal least one year , surgically sterile , practice adequate nonhormonal contraception least 3 month prior duration study participation . All female subject undergo pregnancy test screen checkin clinical study site every dosing period . The result test must negative continued participation . 3 . Weight must within 15 % ideal weight height frame , adopt Metropolitan Life Insurance Co. , 1993 . 4 . Qualifying subject must good health physical condition determine screen medical history obtain within 30 day prior study start . Subjects present history significant past illness expect affect investigation . 5 . The normal status subject confirm follow procedure : 1 . Laboratory test ( chemistry , hematology , urinalysis ) 2 . Human immunodeficiency virus ( HIV ) , hepatitis , alcohol , `` drug abuse '' test do screening purpose . Results HIV , hepatitis , `` drug abuse '' test must negative nonreactive subject qualify study . 3 . Electrocardiogram : A 12lead electrocardiogram ( ECG ) obtain subject . This ECG must interpret appropriately trained experience medical personnel . A subject ECG within normal range qualify , unless specifically accept ( comment ) investigator . 6 . Subjects must able provide write consent agree abide study requirement . 1 . History chronic alcohol , drug , narcotic abuse . 2 . Chronic use tranquilizer , sedative , aspirin , antibiotic , medication . 3 . History presence major organ dysfunction . 4 . History malignancy , stroke , diabetes ; cardiac , renal , liver , pulmonary , severe gastrointestinal disease ; serious illness . 5 . History anxiety , tension , severe agitation , psychosis , mental depression . 6 . Family history diagnosis epilepsy seizure disorder . 7 . History glaucoma . 8 . History acute abdominal condition . 9 . History condition might contraindicate require caution use administration chlorpheniramine/hydrocodone , include : history renal impairment , hepatic biliary tract disease , inflammatory bowel disease , ulcerative colitis , constipation , diarrhea , gastrointestinal obstruction ileus , cardiac disease , hypertension , bladder obstruction , pain difficulty pass urine , systemic lupus erythematosus , head trauma , increase intracranial pressure , pulmonary disease , asthma , history hypersensitivity opiate agonist antihistamine . 10 . Administration investigational drug 30 day prior enrollment study . 11 . Subjects smoke history smoking , use nicotinecontaining product . 12 . Subjects donate blood within 30 day prior study entry , include withdrawn conduct clinical study . 13 . Subjects present acute illness . 14 . Subjects must wear contact lens study . 15 . Subjects take prescription drug within 14 day overthecounter medication ( include herbal preparation ) within 7 day prior dose except standard daily dose multivitamin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>